Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05555732




Registration number
NCT05555732
Ethics application status
Date submitted
22/09/2022
Date registered
27/09/2022
Date last updated
31/05/2024

Titles & IDs
Public title
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Scientific title
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)
Secondary ID [1] 0 0
2022-500802-16-00
Secondary ID [2] 0 0
DS1062-A-U303
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Metastatic Non Small Cell Lung Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Datopotamab Deruxtecan
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Carboplatin
Treatment: Drugs - Cisplatin

Experimental: Dato-DXd + Pembrolizumab + Platinum Chemotherapy - Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab plus platinum chemotherapy (cisplatin 75 mg/m^2 or carboplatin area under the curve [AUC) 5]).

Experimental: Dato-DXd + Pembrolizumab - Participants will be randomized to receive 6.0mg/kg Dato-DXd plus 200 mg pembrolizumab.

Active Comparator: Pembrolizumab + Pemetrexed + Platinum Chemotherapy - Participants will be randomized to receive 200 mg pembrolizumab plus 500 mg/m^2 pemetrexed plus platinum chemotherapy (cisplatin 75 mg/m^2 or carboplatin area under the curve [AUC) 5]).


Treatment: Drugs: Datopotamab Deruxtecan
Dato-DXd will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Treatment: Drugs: Pembrolizumab
Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Treatment: Drugs: Pemetrexed
Pemetrexed will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Treatment: Drugs: Carboplatin
Carboplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.

Treatment: Drugs: Cisplatin
Cisplatin will be administered an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle for up to 4 cycles.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free Survival Based on Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [1] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Primary outcome [2] 0 0
Overall Survival in Participants in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [2] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Secondary outcome [1] 0 0
Objective Response Rate by Blinded Independent Central Review in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [1] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Secondary outcome [2] 0 0
Progression-free Survival by Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [2] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Secondary outcome [3] 0 0
Objective Response Rate by Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [3] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Secondary outcome [4] 0 0
Duration of Response by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [4] 0 0
From date of first objective response (CR or PR) to date of first radiographic disease progression or death due to any cause (whichever occurs first), up to approximately 29 months
Secondary outcome [5] 0 0
Time to Response by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [5] 0 0
From randomization to date of first objective response (CR or PR), up to approximately 29 months
Secondary outcome [6] 0 0
Disease Control Rate by BICR and Investigator in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [6] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 29 months
Secondary outcome [7] 0 0
Progression-free Survival 2 in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [7] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Secondary outcome [8] 0 0
Time to Deterioration in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [8] 0 0
From randomization until disease progression or death (whichever occurs first), up to approximately 57 months
Secondary outcome [9] 0 0
Number of Participants With Treatment-emergent Adverse Events (TEAE) in Participants With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Timepoint [9] 0 0
Up to 57 months
Secondary outcome [10] 0 0
Proportion of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) and Proportion of Participants Who Have Treatment-emergent ADA
Timepoint [10] 0 0
Baseline and up to 57 months

Eligibility
Key inclusion criteria
- Sign and date the Main Informed Consent Form (ICF), prior to the start of any study-
specific qualification procedures.

- Adults =18 at the time the Main ICF is signed.

- Has tumor with PD-L1 TPS <50% as determined by PD-L1 IHC 22C3 pharmDx assay by central
testing.

- Has provided a formalin-fixed tumor tissue sample for the measurement of TROP2 protein
expression and for the assessment of other exploratory biomarkers.

- Has not been treated with systemic anticancer therapy for advanced or metastatic
non-squamous NSCLC.

- Has measurable disease based on local imaging assessment using RECIST v1.1.

- Histologically documented NSCLC that meets all of the following criteria:

- Stage IIIB or IIIC disease and not candidates for surgical resection or
definitive chemoradiation, or Stage IV NSCLC disease at the time of randomization
(based on the American Joint Committee on Cancer, Eighth Edition).

- Documented negative test results for epidermal growth factor receptor (EGFR),
lymphoma kinase (ALK), and proto-oncogene1 (ROS1) actionable genomic alterations
based on analysis of tumor tissue.

- No known actionable genomic alterations in neurotrophic tyrosine receptor kinase
(NTRK), proto-oncogene B-raf (BRAF), rearranged during transfection (RET),
mesenchymal-epithelial transition factor (MET), or other actionable driver
kinases with locally approved therapies.

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at
screening.

- Has an adequate treatment washout period before Cycle 1 Day 1.

- Is willing and able to participate in the collection of patient-reported outcomes
(PRO) data.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Has received prior systemic treatment for advanced/metastatic NSCLC.

- Has received prior treatment with any of the following, including in the
adjuvant/neoadjuvant (for NSCLC) setting:

- Any agent, including an antibody-drug conjugate, containing a chemotherapeutic
agent targeting topoisomerase I.

- TROP2-targeted therapy.

- Any anti-programmed death receptor-1 (PD-1), anti-PD-L1, or anti-PD-ligand 2 (L2)
agent or with an agent directed to another stimulatory or co-inhibitory T-cell
receptor (eg, CTLA-4, OX40, CD137).

- Any other immune checkpoint inhibitors.

- Has received a live vaccine or live-attenuated vaccine within 30 days prior to the
first dose of study drug. For any participant receiving an approved severe acute
respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine, please follow the vaccine
label and/or local guidance.

- Has spinal cord compression or clinically active untreated central nervous system
(CNS) metastases and/or carcinomatous meningitis.

- Uncontrolled or significant cardiovascular disease, including:

- Mean QT interval corrected for heart rate using Fridericia's formula (QTcF)
interval >470 msec regardless of sex.

- Myocardial infarction within 6 months prior to randomization.

- Uncontrolled angina pectoris within 6 months prior to randomization.

- LVEF <50% by ECHO or MUGA scan within 28 days before randomization.

- New York Heart Association Class 2 to 4 congestive heart failure (CHF) at
screening.

- Uncontrolled hypertension within 28 days before randomization.

- Clinically severe pulmonary compromise resulting from intercurrent pulmonary
illnesses.

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.

- History of another primary malignancy (beyond NSCLC) except for:

- Malignancy treated with curative intent and with no known active disease =3 years
before the first dose of study treatment and of low potential risk for
recurrence.

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
of disease.

- Adequately treated carcinoma in situ without evidence of disease.

- Participants with a history of prostate cancer (tumor/node/metastasis stage) of
Stage =T2cN0M0 without biochemical recurrence or progression.

- Has a history of severe hypersensitivity reactions to either the drugs or inactive
ingredients of Dato-DXd, pembrolizumab, carboplatin, cisplatin or pemetrexed.

- Has a history of severe hypersensitivity reactions to other monoclonal antibodies.

- Has known human immunodeficiency virus (HIV) infection that is not well controlled.

- Has active or uncontrolled hepatitis B or C infection.

- Female who is pregnant or breastfeeding or intends to become pregnant.

- Any other medical conditions, including cardiac disease or psychological disorders,
and/or substance abuse.

- Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that
required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis
cannot be ruled out by imaging at screening.

- Has active, known, or suspected autoimmune disease.

- Has clinically significant corneal disease.

- Has had an allogeneic tissue/solid organ transplantation.

- Has received prior radiotherapy =4 weeks of start of study intervention or more than
30 Gy to the lung within 6 months of Cycle 1 Day 1.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/01/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/08/2027
Actual
Sample size
Target
975
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
CRSA/ St Andrews Hospital - Adelaide
Recruitment hospital [2] 0 0
Flinders Medical Centre (Fmc) - Bedford Park
Recruitment hospital [3] 0 0
PSEHOG (Peninsula and South Eastern Haematology and Oncology Group) - Frankston
Recruitment hospital [4] 0 0
Southern Medical Day Care Centre - Wollongong
Recruitment hospital [5] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
3199 - Frankston
Recruitment postcode(s) [4] 0 0
2500 - Wollongong
Recruitment postcode(s) [5] 0 0
QLD 4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
New Jersey
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Utah
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Argentina
State/province [15] 0 0
Ciudad Autonoma de Buenos Aire
Country [16] 0 0
Argentina
State/province [16] 0 0
Mar del Plata
Country [17] 0 0
Argentina
State/province [17] 0 0
Pergamino
Country [18] 0 0
Argentina
State/province [18] 0 0
Rosario
Country [19] 0 0
Argentina
State/province [19] 0 0
San Juan
Country [20] 0 0
Argentina
State/province [20] 0 0
Viedma
Country [21] 0 0
Austria
State/province [21] 0 0
Feldkirch
Country [22] 0 0
Austria
State/province [22] 0 0
Klagenfurt
Country [23] 0 0
Austria
State/province [23] 0 0
Vienna
Country [24] 0 0
Belgium
State/province [24] 0 0
Gent
Country [25] 0 0
Belgium
State/province [25] 0 0
Sint-Niklaas
Country [26] 0 0
Brazil
State/province [26] 0 0
Belo Horizonte
Country [27] 0 0
Brazil
State/province [27] 0 0
Caxias do Sul
Country [28] 0 0
Brazil
State/province [28] 0 0
Curitiba
Country [29] 0 0
Brazil
State/province [29] 0 0
Ijui
Country [30] 0 0
Brazil
State/province [30] 0 0
ItajaA-
Country [31] 0 0
Brazil
State/province [31] 0 0
Pelotas
Country [32] 0 0
Brazil
State/province [32] 0 0
Porto Alegre
Country [33] 0 0
Brazil
State/province [33] 0 0
Rio de Janeiro
Country [34] 0 0
Brazil
State/province [34] 0 0
Santo Andre
Country [35] 0 0
Brazil
State/province [35] 0 0
Sao Paulo
Country [36] 0 0
Brazil
State/province [36] 0 0
Taubate
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec City
Country [38] 0 0
Chile
State/province [38] 0 0
Santiago de Chile
Country [39] 0 0
Chile
State/province [39] 0 0
Santiago
Country [40] 0 0
Chile
State/province [40] 0 0
ViAaa Del Mar
Country [41] 0 0
China
State/province [41] 0 0
Beijing Sheng
Country [42] 0 0
China
State/province [42] 0 0
Beijing
Country [43] 0 0
China
State/province [43] 0 0
Cangzhou
Country [44] 0 0
China
State/province [44] 0 0
Changchun
Country [45] 0 0
China
State/province [45] 0 0
Changsha
Country [46] 0 0
China
State/province [46] 0 0
Chengdu
Country [47] 0 0
China
State/province [47] 0 0
Chongqing
Country [48] 0 0
China
State/province [48] 0 0
Fuzhou
Country [49] 0 0
China
State/province [49] 0 0
Guangzhou
Country [50] 0 0
China
State/province [50] 0 0
Hangzhou
Country [51] 0 0
China
State/province [51] 0 0
Harbin
Country [52] 0 0
China
State/province [52] 0 0
Hefei
Country [53] 0 0
China
State/province [53] 0 0
Hohhot
Country [54] 0 0
China
State/province [54] 0 0
Jiamusi
Country [55] 0 0
China
State/province [55] 0 0
Linyi
Country [56] 0 0
China
State/province [56] 0 0
Nanchang
Country [57] 0 0
China
State/province [57] 0 0
Nanjing
Country [58] 0 0
China
State/province [58] 0 0
Shanghai
Country [59] 0 0
China
State/province [59] 0 0
Shenyang
Country [60] 0 0
China
State/province [60] 0 0
Wuhan
Country [61] 0 0
China
State/province [61] 0 0
Xi'an
Country [62] 0 0
China
State/province [62] 0 0
Xianyang
Country [63] 0 0
China
State/province [63] 0 0
Zhengzhou
Country [64] 0 0
China
State/province [64] 0 0
Ürümqi
Country [65] 0 0
France
State/province [65] 0 0
Bordeaux
Country [66] 0 0
France
State/province [66] 0 0
France
Country [67] 0 0
France
State/province [67] 0 0
Lyon
Country [68] 0 0
France
State/province [68] 0 0
Marseille Cedex 20
Country [69] 0 0
France
State/province [69] 0 0
Montpellier Cedex 5
Country [70] 0 0
France
State/province [70] 0 0
Nantes
Country [71] 0 0
France
State/province [71] 0 0
Paris
Country [72] 0 0
France
State/province [72] 0 0
Suresnes
Country [73] 0 0
Germany
State/province [73] 0 0
Berlin
Country [74] 0 0
Germany
State/province [74] 0 0
Chemnitz
Country [75] 0 0
Germany
State/province [75] 0 0
Essen
Country [76] 0 0
Germany
State/province [76] 0 0
Esslingen
Country [77] 0 0
Germany
State/province [77] 0 0
Muenster
Country [78] 0 0
Germany
State/province [78] 0 0
Munich
Country [79] 0 0
Greece
State/province [79] 0 0
Athens
Country [80] 0 0
Greece
State/province [80] 0 0
Heraklion
Country [81] 0 0
Greece
State/province [81] 0 0
Ioannina
Country [82] 0 0
Greece
State/province [82] 0 0
Neo Faliro
Country [83] 0 0
Greece
State/province [83] 0 0
Thessalonki
Country [84] 0 0
Hong Kong
State/province [84] 0 0
Hong Kong
Country [85] 0 0
Hong Kong
State/province [85] 0 0
Pok Fu Lam
Country [86] 0 0
Hungary
State/province [86] 0 0
Budapest
Country [87] 0 0
Hungary
State/province [87] 0 0
Farkasgyepu
Country [88] 0 0
Hungary
State/province [88] 0 0
KecskemAŠt
Country [89] 0 0
Hungary
State/province [89] 0 0
Szekesfehervar
Country [90] 0 0
Hungary
State/province [90] 0 0
Szolnok
Country [91] 0 0
Italy
State/province [91] 0 0
Candiolo
Country [92] 0 0
Italy
State/province [92] 0 0
Orbassano
Country [93] 0 0
Italy
State/province [93] 0 0
Udine
Country [94] 0 0
Italy
State/province [94] 0 0
Varese
Country [95] 0 0
Italy
State/province [95] 0 0
Verona
Country [96] 0 0
Japan
State/province [96] 0 0
Azuma
Country [97] 0 0
Japan
State/province [97] 0 0
Bunkyo-Ku
Country [98] 0 0
Japan
State/province [98] 0 0
Fukuoka
Country [99] 0 0
Japan
State/province [99] 0 0
Hataji
Country [100] 0 0
Japan
State/province [100] 0 0
Hirakata
Country [101] 0 0
Japan
State/province [101] 0 0
Iwakuni
Country [102] 0 0
Japan
State/province [102] 0 0
Kanazawa-shi
Country [103] 0 0
Japan
State/province [103] 0 0
Kanemaru
Country [104] 0 0
Japan
State/province [104] 0 0
Kofu
Country [105] 0 0
Japan
State/province [105] 0 0
Koto
Country [106] 0 0
Japan
State/province [106] 0 0
Kozuki
Country [107] 0 0
Japan
State/province [107] 0 0
Kumamoto
Country [108] 0 0
Japan
State/province [108] 0 0
Kyoto
Country [109] 0 0
Japan
State/province [109] 0 0
Matsusaka
Country [110] 0 0
Japan
State/province [110] 0 0
Niigata
Country [111] 0 0
Japan
State/province [111] 0 0
Nishinomiya
Country [112] 0 0
Japan
State/province [112] 0 0
Okamato
Country [113] 0 0
Japan
State/province [113] 0 0
Sapporo-shi
Country [114] 0 0
Japan
State/province [114] 0 0
Sendai
Country [115] 0 0
Japan
State/province [115] 0 0
Shimotsuga-gun
Country [116] 0 0
Japan
State/province [116] 0 0
Toyonaka-shi
Country [117] 0 0
Japan
State/province [117] 0 0
Ube-shi
Country [118] 0 0
Japan
State/province [118] 0 0
Yokohama
Country [119] 0 0
Korea, Republic of
State/province [119] 0 0
Cheongjusi
Country [120] 0 0
Korea, Republic of
State/province [120] 0 0
Daegu
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Gangnam-Gu
Country [122] 0 0
Korea, Republic of
State/province [122] 0 0
Goyang-si
Country [123] 0 0
Korea, Republic of
State/province [123] 0 0
Jinju-si Gyeongsangnam-do
Country [124] 0 0
Korea, Republic of
State/province [124] 0 0
Seongnam-si
Country [125] 0 0
Korea, Republic of
State/province [125] 0 0
Seoul
Country [126] 0 0
Netherlands
State/province [126] 0 0
Breda
Country [127] 0 0
Netherlands
State/province [127] 0 0
Leiden
Country [128] 0 0
Netherlands
State/province [128] 0 0
s-Hertogenbosch
Country [129] 0 0
Poland
State/province [129] 0 0
Lodz
Country [130] 0 0
Poland
State/province [130] 0 0
Poznan
Country [131] 0 0
Romania
State/province [131] 0 0
Cluj- Napoca
Country [132] 0 0
Romania
State/province [132] 0 0
Craiova
Country [133] 0 0
Romania
State/province [133] 0 0
Timisoara
Country [134] 0 0
Spain
State/province [134] 0 0
Barcelona
Country [135] 0 0
Spain
State/province [135] 0 0
Lleida
Country [136] 0 0
Spain
State/province [136] 0 0
Madrid
Country [137] 0 0
Spain
State/province [137] 0 0
Malaga
Country [138] 0 0
Spain
State/province [138] 0 0
Ourense
Country [139] 0 0
Spain
State/province [139] 0 0
Sevilla
Country [140] 0 0
Spain
State/province [140] 0 0
Valenica
Country [141] 0 0
Spain
State/province [141] 0 0
Zaragoza
Country [142] 0 0
Switzerland
State/province [142] 0 0
Liestal
Country [143] 0 0
Switzerland
State/province [143] 0 0
St. Gallen
Country [144] 0 0
Switzerland
State/province [144] 0 0
Thun
Country [145] 0 0
Taiwan
State/province [145] 0 0
Hsia
Country [146] 0 0
Taiwan
State/province [146] 0 0
Taipei
Country [147] 0 0
Thailand
State/province [147] 0 0
Bangkok
Country [148] 0 0
Thailand
State/province [148] 0 0
Chiang Mai
Country [149] 0 0
Thailand
State/province [149] 0 0
Hat Yai
Country [150] 0 0
Thailand
State/province [150] 0 0
Mueang Nonthaburi
Country [151] 0 0
Turkey
State/province [151] 0 0
Adana

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Daiichi Sankyo
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
AstraZeneca
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/Industry
Name [2] 0 0
Merck Sharp & Dohme LLC
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd)
in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and
platinum chemotherapy in participants with no prior therapy for advanced or metastatic
non-squamous non-small cell lung cancer (NSCLC).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05555732
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Leader
Address 0 0
Daiichi Sankyo
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information
Address 0 0
Country 0 0
Phone 0 0
908-992-6400
Fax 0 0
Email 0 0
CTRinfo@dsi.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05555732